

Literaturverzeichnis

- [1] Augustin, M., P. R. Bock, J. Hanisch, M. Karasmann and B. Schneider, *Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract*. *Arzneim -Forsch /Drug Res* 55, 38-49 (2005).

- [2] Kienle, G. S. and H. Kiene, *Stellenwert, Dosierung und Gefährlichkeit (Tumorenhancement) des ML I - immunologische Schlußfolgerungen und experimentelle Untersuchungen*. In *Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen*. pp. 301-332, Schattauer Verlag, Stuttgart, New York 2003.

- [3] Kleeberg, U. R., S. Suci, E. B. Bröcker, D. J. Ruiter, C. Chartier, D. Liénard, J. Marsden, D. Schadendorf and A. M. M. Eggermont, *Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN- α 2b versus rIFN-g versus Iscador M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis*. *Eur J Cancer* 40, 390-402 (2004).